Neuromodulation

AUA/SUFU Guideline on the Treatment of Overactive Bladder Allows Access to ReviTM System Earlier in Treatment Journey

Retrieved on: 
월요일, 4월 29, 2024
FDA, Commercial software, Society, Risk, Urinary incontinence, Food, De novo, American Urological Association, Paruresis, Pharmacotherapy, MMHC, Guideline, OAB, Deficit spending, Prescription, Patient, Neuromodulation, Physician, AUA, Ankle, Diagnosis, SUFU, Anticholinergic, Female

The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI.

Key Points: 
  • The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI.
  • First, the guidelines were updated to include iTNM as an acceptable minimally invasive therapy.
  • "We are delighted to witness the transformation of the new OAB treatment guideline by the AUA/SUFU.
  • This guideline represents a significant turning point in physicians' approach to OAB management," commented Dan Lemaitre, Chief Executive Officer of BlueWind Medical.

Integer Holdings Corporation Reports First Quarter 2024 Results

Retrieved on: 
목요일, 4월 25, 2024
Neuromodulation, Arrhythmia, Growth, Acquisition, EPS, PMA, GAAP, Electrophysiology, Electrochemistry

PLANO, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 29, 2024.

Key Points: 
  • PLANO, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 29, 2024.
  • First Quarter 2024 Highlights (compared to First Quarter 2023, except as noted)
    Sales increased 10% to $415 million, with organic growth of 6%.
  • Cardiac Rhythm Management & Neuromodulation sales increased 8% in the first quarter 2024 compared to the first quarter 2023, with strong growth in emerging Neuromodulation customers with PMA (pre-market approval) products and strong demand in Cardiac Rhythm Management.
  • Electrochem sales decreased in the first quarter 2024 compared to the first quarter 2023, returning to a normalized run-rate after previously higher sales from the supply chain recovery.

LivaNova Reports First-Quarter 2024 Results

Retrieved on: 
수요일, 5월 1, 2024
Neurology, Cardiology, Biotechnology, Health, FDA, Mental Health, Medical Devices, Health Technology, LivaNova, Wind, Table, ACS, Telephone, GAAP, News, Growth, Neuromodulation, Video game

Includes the results from the wind down portion of the Company's former ACS reportable segment.

Key Points: 
  • Includes the results from the wind down portion of the Company's former ACS reportable segment.
  • Segment financial information presented herein reflects LivaNova's change in segments, effective in the first quarter 2024, for all periods presented.
  • LivaNova now expects revenue for full-year 2024 to grow between 6 and 7 percent on a constant-currency basis.
  • Adjusted diluted earnings per share for 2024 are now expected to be in the range of $3.05 to $3.15, assuming a share count of approximately 55 million for full-year 2024.

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

Retrieved on: 
수요일, 4월 24, 2024
Cosmetics, Lifestyle, Retail, Health, Consumer, Pharmaceutical, USD, Core, Corporation, FDA, American Academy, Prurigo nodularis, SWX, International, Social, Acne, Super Bowl, Aesthetics, Dermatology, Business ethics, Sustainalytics, Chinese New Year, Neuromodulation, Filler (animal food), Bowl game, IPO, Science, Patient, ESG, AAD, Atopic dermatitis, Growth, Corporate governance, SIX Swiss Exchange, Pharmaceutical industry

Year-on-year net sales growth on a constant currency basis for the period was 12.4%, primarily driven by volume.

Key Points: 
  • Year-on-year net sales growth on a constant currency basis for the period was 12.4%, primarily driven by volume.
  • Injectable Aesthetics net sales for the first quarter of 2024 were 511 million USD, with year-on-year growth of 19.3% on a constant currency basis.
  • Dermatological Skincare net sales for the first quarter of 2024 were 351 million USD, with year-on-year growth of 8.4% on a constant currency basis.
  • Therapeutic Dermatology net sales for the first quarter of 2024 were 209 million USD, with year-on-year growth of 4.1% on a constant currency basis.

Medtronic receives FDA approval for Inceptiv™ closed-loop spinal cord stimulator

Retrieved on: 
금요일, 4월 26, 2024
Sale, FDA, Brain, Patient, SCS, Spinal cord stimulator, Neuromodulation, Food, Neuroscience, Medtronic, Spinal cord, Sneeze, Google Images, MRI, RCT, Connective tissue, ECAPS, Chronic pain, Medical imaging

DUBLIN, April 26, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.

Key Points: 
  • Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.
  • Traditional fixed-output SCS devices deliver constant, mild electrical impulses that disrupt pain signals before they reach the brain.
  • Specialized circuitry and a proprietary algorithm detect ECAPs (Evoked Compound Action Potentials), signals generated by the spinal cord in response to electrical stimuli.
  • ECAPs are a direct measure of how much nerve tissue is activated in the spinal cord and can be used to inform real-time adjustments to stimulation.

iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors

Retrieved on: 
월요일, 4월 22, 2024
Guidant, Medicine, Patient, Doctor of Philosophy, Boston Scientific, Neuromodulation

MINNEAPOLIS, April 22, 2024 /PRNewswire/ -- iVEAcare, a privately held, development stage medical device company, announced the close of a $27.5 million Series A financing.

Key Points: 
  • MINNEAPOLIS, April 22, 2024 /PRNewswire/ -- iVEAcare, a privately held, development stage medical device company, announced the close of a $27.5 million Series A financing.
  • The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner.
  • iVEAcare is the third spin-off from NuXcel, a medical device accelerator that is managed by Mudit K. Jain, PhD and Lynn Elliott and backed by Treo Ventures.
  • This Series A financing enables iVEAcare to deliver innovative neuromodulation therapy to patients and clinicians," Kerkow said in prepared remarks.

Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation

Retrieved on: 
금요일, 4월 12, 2024
Leg, Brain, Inflammation, College of Engineering (KNUST), Post-traumatic stress disorder, Safety, Neuromodulation, Science Advances, Animal, Field line, Hand, Pathology, Depression, Tic disorder, Motor cortex, Mental health, Patient, Spinal cord, Miniature, DOT, DSM-IV codes, Transcranial magnetic stimulation, Digital, Manuscript, Rice University, TMS

HOUSTON, April 12, 2024 /PRNewswire/ -- Rice University today announced that Jacob Robinson, a professor of electrical and computer engineering and of bioengineering and founder and chief executive officer of Motif Neurotech, a neurotechnology company developing minimally invasive bioelectronics for mental health formed through the Rice Biotech Launch Pad, published a peer-reviewed study in Science Advances detailing a novel and wireless device - an epidural cortical stimulator known as the Digitally programmable Over-brain Therapeutic (DOT), that is capable of receiving enough energy to stimulate human and large-animal brain activity and can deliver bursts of electrical stimulation to the brain through the dura, the tough membrane that covers the brain and the spinal cord. The manuscript entitled "Miniature battery-free epidural cortical stimulators" can be viewed on the Science Advances website.

Key Points: 
  • The manuscript entitled " Miniature battery-free epidural cortical stimulators " can be viewed on the Science Advances website.
  • "However, current neuromodulation devices are either bulky, invasive, or limited in their stimulation capabilities.
  • It overcomes challenges by using a battery-free and wireless approach  to create an implant that can deliver precise and programmable stimulation to the brain, without brain surgery."
  • The study details how the DOT stimulator works by using magnetoelectric antennas that can convert magnetic fields into electric fields and vice versa.

SpineX Closes Recruitment for SCONE™ Clinical Trial

Retrieved on: 
월요일, 4월 8, 2024
Children, Biotechnology, FDA, Health, Neurology, Health Technology, Medical Devices, Research, Consumer, Science, Clinical Trials, Cord, Brain, Cerebral palsy, Multiple sclerosis, SCIP, Patient, Stroke, Clinical trial, Urinary bladder, Trial of the century, Skin, Spinal cord, Heart, Urinary incontinence, Cauda equina syndrome, Neuromodulation, Pharmaceutical industry

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.

Key Points: 
  • SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
  • The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
  • “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
  • SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.

BlueWind Medical Revi™ Patient-Centric Solution for Urge Urinary Incontinence Now Available at Mount Carmel Health in Ohio

Retrieved on: 
화요일, 4월 9, 2024
Physician, Patient, Tibial, OASIS, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Safety, Commercial software, Neuromodulation, FDA, Medical device

PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).

Key Points: 
  • PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).
  • "Many of my patients are looking for an alternative to ongoing drug therapy" shared Dr. Jeffrey Carey.
  • "Revi provides individually tailored therapy that patients deliver themselves, on their schedule, and at their convenience.
  • Coupled with the excellent safety and efficacy of Revi, it's a welcome choice for urge incontinence patients."

Patients in Utah Now Have Access to the Novel Revi™ Implantable Tibial Neuromodulation Device for the Treatment of Urge Urinary Incontinence

Retrieved on: 
수요일, 3월 27, 2024
Physician, Patient, OASIS, University, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Commercial software, Neuromodulation, FDA

PARK CITY, Utah, March 27, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient-centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Utah with urologist Dr. Sara Lenherr at the University of Utah.

Key Points: 
  • "Revi is a solution for the millions of people dealing with Urge Urinary Incontinence (UUI).
  • I look forward to offering Revi to my patients, especially those who are unable to tolerate, afford, or are not good candidates for drug therapy," shared Dr. Sara Lenherr.
  • "Revi offers a patient-centered design, which allows for individually tailored therapy that patients can deliver themselves, on their schedule and at their convenience."
  • UUI is a common and debilitating condition, affecting approximately 16 million people in the U.S., most of whom never receive effective treatment.